News, Publications & Presentations
Immodulon’s Chief Scientific Officer, Laura Rosa Brunet, speaks at Targeted Anticancer Therapies Congress
Immodulon attended the 15th International Congress on Targeted Anticancer Therapies (TAT), which took place from the 6th- 8th March in Paris. TAT congresses are annual meetings on new molecular targets and innovative cancer therapeutics in the early phases of clinical...
Grant awarded to Professor Stefan Reber for work involving IMM-201
The Office of Naval Research, which is part of the US Department of Defence, has awarded a grant of up to two years of support to Professor Stefan Reber (Laboratory for Molecular Psychosomatics, University of Ulm, Germany) for his work on the promotion of stress...
Immodulon’s Chief Scientific Officer speaks at Immuno-Oncology 360°
Immodulon attended the 3rd annual Immuno‑Oncology 360° event taking place February 1st - 3rd, 2017 in New York. Immuno-Oncology 360° is a global conference attracting national and international experts and thought leaders from large pharmaceuticals and...
Study led by Dr Christopher Lowry linking beneficial bacteria to mental health makes top 10 list for brain research
A CU Boulder study led by Immodulon Scientific Advisory Board member Dr Christopher Lowry showing that injecting beneficial bacteria into mice can make them more resilient to stress has been named among the “top 10 advancements and...
The Effect of IMM-101 on Dendritic Cells and Adaptive Immune Response
Data from an ongoing collaboration between the laboratory of Prof. Andrew MacDonald at Manchester Collaborative Centre for Inflammation Research (University of Manchester, Manchester, UK) and Immodulon Therapeutics shedding light on adaptive immune responses initiated...
Poster presented on the effects of Combination Treatment of IMM-101 at 2016 Annual meeting of the Society for Immunotherapy
Data from an ongoing collaboration between Immodulon Therapeutics and the laboratory of Prof. Andrew MacDonald at Manchester Collaborative Centre for Inflammation Research (University of Manchester, Manchester UK) on the effects of combination treatment of IMM‑101 (a...
Immodulon is sad to announce the death of founding member, Professor John Grange
It is with great sadness that Immodulon announces the passing of Professor John Grange, one of the founding members of Immodulon. John played a crucial role in establishing the company for which the entire Immodulon team will always be extremely grateful. His death is...
Positive data from phase II study of IMM-101 in combination with gemcitabine in advanced pancreatic cancer
In IMAGE-1, a phase II proof-of-concept study recruiting 110 patients with locally advanced or metastatic pancreatic cancer, patients were randomized to receive IMM‑101 + gemcitabine or gemcitabine alone. This study was designed to provide indicative rather than...
Poster presented at 2016 Biennial Congress of European Association For Cancer Research
Further data from an ongoing collaboration between the laboratory of Prof. Andrew MacDonald at Manchester Collaborative Centre for Inflammation Research (University of Manchester, Manchester, UK) and Immodulon Therapeutics on the effects of IMM-101 (a heat-killed...
IMM-201 pre-clinical data published in peer-reviewed journal
Results from pre-clinical research conducted at the University of Colorado Boulder in the USA led by Dr Chris Lowry, as part of an agreement with Immodulon to test Mycobacterium vaccae NCTC11659 in a variety of laboratory models of mental health disorders. Full title:...
Immodulon publishes review article on Immune monitoring technology
In this review, Immodulon in collaboration with Myriad Rule Based Medicine (USA) describes the TruCulture® system. This technology applied to small whole blood sample permits investigation of immunological activity following immune stimulation resulting in synthesis...
Poster presented at 2016 Keystone symposium on Cancer Immunotherapy
A collaboration between the laboratory of Prof. Andrew MacDonald at Manchester Collaborative Centre for Inflammation Research (University of Manchester, Manchester, UK) and Immodulon Therapeutics investigating the effects of IMM-101 (a heat-killed whole cell...
Immodulon announces publication of pre-clinical data in peer-reviewed journal
A collaboration between the laboratory of Prof. George Bahr at the University of Balamand, Lebanon and Immodulon Therapeutics investigating the effects of IMM‑101 (a heat-killed whole cell preparation of Mycobacterium obuense NCTC13365) on various cells of the immune...
Immodulon publishes review article on new immune-related strategies to treat metastatic pancreatic cancer
In this review, Immodulon along with clinical collaborators gives an overview of new immune-related therapeutic strategies currently being tested in clinical trials in metastatic pancreatic cancer. This paper proposes that immunotherapeutic strategies in combination...
Update on open label phase II study of IMM-101 in advanced melanoma
An Open Label Long‑term Follow‑up Study for Patients with Melanoma who were previously Enrolled in the Phase I Study IMM‑101‑001Phase I EudraCT No. 2011-003967-31 ClinicalTrials.gov NCT01559818 Following the completion of study IMM‑101‑001, patients were given the...
Dr James Shannon appointed to Immodulon Therapeutics Board of Directors
LONDON, UK – Thursday 23 July, 2015 – Immodulon Therapeutics, a privately held, late-stage biopharmaceutical company focused on immuno-oncology, has made a new senior appointment to its Board ofDirectors to support its continued growth and development. Dr James...
Immodulon Therapeutics announces new appointments to Board of Directors
LONDON, UK – Wednesday 10 June, 2015 – Immodulon Therapeutics, a privately held, late-stage biopharmaceutical company focused on immuno-oncology, has made two new senior appointments to its Board of Directors to support its continued growth. Anthony Bolton, one of the...
Immodulon Therapeutics announce Orphan Drug Designation for IMM-101 in EU in the treatment of pancreatic cancer
LONDON, UK – December 16, 2014 - Immodulon Therapeutics today announced that Orphan designation EU/3/14/1385 was granted by the European Commission for IMM-101, heat-killed Mycobacterium obuense (whole cell) for the treatment of pancreatic...
IMM-101 induces protective responses in preclinical models of cancer
Collaborations between Immodulon Therapeutics and academic laboratories in London Universities are yielding new data showing promising therapeutic effects of treatment with IMM-101 (a heat-killed whole cell preparation of Mycobacterium obuense...
Immodulon Therapeutics announce Orphan Drug Designation for IMM-101 in US in the treatment of pancreatic cancer
LONDON, UK – September 23, 2014 - Immodulon Therapeutics today announced that Orphan designation was granted by the FDA for IMM-101, heat-killed Mycobacterium obuense (whole cell) for the treatment of pancreatic cancer.